摘要
[目的]探讨他扎罗汀诱导基因3(TIG3)在肝癌中的表达情况及其抑制作用。[方法]在临床病理组织标本中,通过免疫组化检测肝癌组织和正常肝组织TIG3、核增殖抗原(Ki67)蛋白表达情况。在细胞系中,采用实时定量PCR技术,检测TIG3在正常肝细胞与肝癌细胞中表达情况;利用脂质体2000向TIG3内在表达量最低的细胞中,转染TIG3过表达质粒,通过荧光定量PCR检测转染效果,同时再通过MTT比色法探讨过表达TIG3对肝癌细胞活力的影响。[结果]在临床病理组织标本中,TIG3在肝癌组织中低表达,且与Ki67的表达呈负相关;细胞功能研究发现,过表达TIG3可使肝癌细胞活力下降,肝癌细胞生长增殖受到抑制。[结论]TIG3在肝癌组织中低表达,且可抑制肝癌生长增殖,因此TIG3可能作为肝癌分子靶向治疗新靶点。
[Objective]To explore the expression of tazarotene-induced gene 3（TIG3）in hepatocellular carcinoma and its inhibitory effect.[Methods]With the immunohistochemistry of clinical specimens,TIG3 and Ki67protein was detected in hepatocellular carcinoma tissues and adjacent normal tissues.Meanwhile,in cell lines level,the expression of TIG3 in normal liver cells and liver cancer cells was determined by real time quantitative PCR.The cell which expressed the minimum quantity of TIG3 was transfected transiently with TIG3 overexpressed plasmid by using lipofectamine 2000.After cell transfection,real time quantitative PCR was used to evaluate the effect of transfection.At the same time,the role of TIG3 overexpression in the liver cancer cell viability was evaluated by MTT assay.[Results]In the clinical samples,TIG3 was low expression in hepatocellular carcinoma tissues,and it was negatively related to the expression of Ki-67 protein in hepatocellular carcinoma tissue.In the subsequent experiment of cell function,overexpression of TIG3 could make the liver cancer cell viability decrease and inhibit the growth of liver cancer cell.[Conclusion]TIG3is low expression in hepatocellular carcinoma,and it can inhibit the proliferation of HCC,so TIG3 can be used as a new molecular therapy target of HCC.
出处
《临床消化病杂志》
2015年第4期193-196,共4页
Chinese Journal of Clinical Gastroenterology
关键词
肝细胞癌
他扎罗汀诱导基因3
分子靶向治疗
hepatocellular carcinoma
tazarotene-induced gene 3
molecular therapy target
